European Society of Hypertension-ESH Education-Congress Reports,Scientific Sessions 2004,Pioglitazone

Congress Reports

ESHonline Coverage, based on selected sessions at the:
American Heart Association 2004 Annual Scientific Sessions
November 7 - 10, 2004, New Orleans, Louisiana

This activity is not sanctioned by, nor a part of, the Americann Heart Association.

Pioglitazone Improves Lipid Profile Beyond Glycemic Control

November 10, 2004 (eshonline.org) - In patients with type II diabetes and dyslipidemia, pioglitazone significantly improved triglycerides, HDL-cholesterol, non-HDL-cholesterol, and LDL particle concentration and size, compared to rosiglitazone in a 24-week comparison in 735 patients (56 years old, 50% male). Glycemic control was the same in both groups. Blood pressure data was not collected or reported. Data on weight changes are being analyzed and will be reported soon.

In this multicenter, double-blind trial, led by Dr. Ronald Goldberg, University of Miami School of Medicine, prior medications for diabetes were discontinued for 4 weeks prior to randomization. The maximally effective doses at 12 weeks were 30 mg pioglitazone daily and 4 mg rosiglitazone daily. The head-to-head comparison was designed to clarify the effect of the 2 agents on serum lipids.

Week 24 Changes from Baseline in Comparison of Pioglitazone and Rosiglitazone

	PIO	PIO	ROSI	ROSI
	Mean change	% change	Mean change	% change
TG (mg/dL)	-51.0*	-12.0*	+13.1	+14.9
HDL-C (mg/dL	+5.2*	+14.9*	+2.4	+7.8
Non-HDL-C (mg/dL)	+3.6*	+3.8*	+25.7	+18.6
LDL-C (mg/dL)	+12.3*	+15.7*	+21.3	+23.3
LDL particle concentration (nmol/L)	-50.5*	-7.8*	+110	+12.0
LDL particle size (nm)	+0.46**	+2.4**	+0.33	+1.7
Apolipoprotein B (g/L)	<0.01*	+1.5*	+0.11	+11.5

*P<0.001 or **P=0.005, between groups. PIO, pioglitazone (n=363), ROSI, rosiglitazone (n=356).

The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the American Heart Association. These materials and the related activity are not sanctioned by the American Heart Association and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.